αPD-1-ABD-PE selectively binds and penetrates PD-1 + cells. αPD-1-ABD-PE has three functional components: αPD-1 (scFv),
A utoimmune diseases are primarily mediated by autoreactive lymphocytes and/or their secreted autoantibodies [1] [2] [3] [4] . Targeted suppression of certain lymphocyte populations is an effective strategy to treat these diseases, which has yielded new therapies for multiple sclerosis (MS) and systemic lupus erythematosus (SLE) [5] [6] [7] [8] . However, these therapies are rarely considered as first-line therapeutic options due to their indiscriminate inhibition of normal adaptive immunity 6, [9] [10] [11] [12] . This inhibition occurs because these therapies target lymphocytes too broadly [4] [5] [6] 11 . Thus, identification and selective suppression of pathogenic lymphocytes responsible for autoimmune diseases while keeping non-pathologic lymphocytes intact constitutes an overarching yet unmet clinical goal.
Cells expressing programmed-cell-death-protein-1 (PD-1) are primarily activated B and T cells or effector B and T cells [13] [14] [15] . PD-1, a negative receptor of these cells, switches on the PD-1 immune checkpoint when engaged by its ligands. This critical checkpoint counteracts immune-stimulatory signals and limits PD-1 + effector cells from initiating autoimmune destruction [16] [17] [18] [19] [20] [21] [22] [23] . However, in type 1 diabetes (T1D), MS, SLE, and rheumatoid arthritis, the PD-1 checkpoint fails to stop autoimmune destruction 16, 21 . Instead, PD-1 + cells infiltrate tissues 17, 19 , and this infiltration escalates as the autoimmune diseases progress 19 . These observations indicate that PD-1 + cells are important mediators of autoimmune diseases. Consistent with this concept, the blockade of the PD-1 checkpoint, which leads to a proliferation of PD-1 + cells, exacerbates autoimmune diseases in both human and mouse models 19, [24] [25] [26] . Taken together, the targeted depletion of PD-1 + cells in the context of autoimmune diseases might be an effective method to assuage autoimmunity. It is worth mentioning that PD-1 + cell depletion is a very different concept to ablation of the PD-1 gene. PD-1 + cell depletion eliminates activated lymphocytes; by contrast, the knockout of the PD-1 gene leaves activated lymphocytes uncontrolled by the PD-1 checkpoint and enables uncontrolled proliferation of activated lymphocytes 21 . Thus, whereas PD-1 + knockout predisposes the host to enhanced autoimmunity, we hypothesize that PD-1 + cell depletion suppresses autoimmunity.
There are two intrinsic advantages to using PD-1 + cell depletion. First, the depletion should leave naive (PD-1 − ) lymphocytes intact, and hence preserve B-and T-cell repertoires because the depletion primarily applies to activated lymphocytes. PD-1 + cell depletion should not substantially compromise normal adaptive immunity. This distinguishes PD-1 + cell depletion from drugs currently used to treat autoimmune diseases, such as natalizumab and alematuzumab 5, 6, 11 . Second, PD-1 + cell depletion applies to both activated B cells and activated T cells, since both cell types are PD-1 + . The dual coverage of both activated B and T cells is advantageous because the both cell types can contribute to autoimmune diseases 3 .
Here, we describe a fusion protein, containing a single-chain variable fragment (scFv) of the PD-1 antibody (αPD-1) 27 , an albumin-binding domain (ABD) 28, 29 , and a Pseudomonas aeruginosa exotoxin A (PE) 30, 31 , as a tool for PD-1 + cell depletion. In the resulting immunotoxin (αPD-1-ABD-PE), αPD-1 serves as a targeting moiety, ABD is used to extend plasma presence, because ABDcontaining molecules have a long half-life in plasma 28, 29, 32 , whereas PE has been demonstrated to have clinical efficacy and is safe 30, 33 . αPD-1-ABD-PE possesses selective toxicity, both in vitro and in vivo, to PD-1 + cells. More importantly, αPD-1-ABD-PE not only halted the progression of autoimmune diseases in our systems, but also concomitantly preserved normal adaptive immunity.
ABD and PE (Fig. 1a ). The amino acid sequences of ABD and PE have been previously published 31, 34 . We sequenced RMP1-14, a rat monoclonal antibody raised against mouse PD-1 (IgG2a, κ) 35 . On the basis of these sequencing results, we designed αPD-1 to contain two mutations, V H (R45C) and V L (G104C) (Fig. 1b ). The two cysteines were introduced to form a disulfide bond and enhance stability of αPD-1 36 . A linker, (GGGGS) 3 , was used to connect αPD-1, ABD and PE. We also designed three control proteins for this study: αPD-1, ABD-PE, and αPD-1-PE (Fig. 1a ). All of these proteins have a histidine tag (HisTag) to facilitate purification. The coding genes for αPD-1-ABD-PE and the control proteins were cloned into the pET25b(+) vector. The sizes of the cloned genes were confirmed by agarose gel electrophoresis ( Supplementary Fig. 1a ), and the genes were sequenced and confirmed to have the designed sequences. αPD-1-ABD-PE and the control proteins were produced and purified as soluble proteins from Escherichia coli (Shuffle T7) that harboured the expression vectors. The yield was approximately 0.3 mgl −1 culture for each of the proteins. The purity and size of these proteins were examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ( Supplementary Fig. 1b ). The sizes of these proteins were consistent with their predicted theoretical molecular masses; for example, αPD-1-ABD-PE migrated slightly lower than the 63 kDa marker, in agreement with its theoretical molecular mass of 57.9 kDa. Endotoxins were removed from all purified proteins to 0.1 U per mg protein.
In comparisons between PD-1 + and PD-1 − cells of different types, we found that αPD-1-ABD-PE selectively binds to PD-1 + cells. We compared PD-1 + and PD-1 − primary T cells, PD-1 + and PD-1 − primary B cells, and EL4 (PD-1 + ) 37 and B16-F10 (hereafter referred to as B16) (PD-1 − ) cells ( Supplementary Fig. 2a,b ). We incubated Alexa Fluor 647-labelled αPD-1-ABD-PE with PD-1 + and PD-1 − cells, separately at 4 °C (30 min), whereby cell-surface binding could occur but internalization was inhibited. After incubation, the mean fluorescence intensity (MFI) of the PD-1 + primary T cells was more than four times that of the PD-1 − primary T cells (188.33 ± 5.92 versus 43.45 ± 2.98; Fig. 1c ); the MFI of the PD-1 + primary B cells was more than five times that of the PD-1 − primary B cells (229.67 ± 12.45 versus 43.72 ± 2.46; Fig. 1d ); and the MFI of EL4 cells was more than three times that of the B16 cells (571.70 ± 12.12 versus 116.00 ± 1.61; Supplementary Fig. 2c ). By contrast, both the PD-1 + and the PD-1 − cells had low MFI after similar incubations with labelled ABD-PE ( Fig. 1c,d and Supplementary Fig. 2c ). Using a dose-responsive binding assay, we found that the apparent dissociation constant (K d ) of αPD-1-ABD-PE on PD-1 − EL4 cells is 12.0 nM (95% confidence interval (CI) = 8.7-16.5 nM), whereas the K d value of intact αPD-1 is 3.4 nM (95% CI = 2.2-5.2 nM; Supplementary Fig. 2d ), indicating that αPD-1-ABD-PE has a weaker affinity for the EL4 cells than does intact αPD-1.
We also incubated the labelled αPD-1-ABD-PE with the PD-1 + and the PD-1 − cells separately at 37 °C (30 min), whereby both cellsurface binding and internalization could progress. After incubation, the MFI of the PD-1 + primary T cells, as measured by flow cytometry, was more than eight times that of the PD-1 − primary T cells (341.17 ± 31.97 versus 42.13 ± 2.00; Fig. 1e ); the MFI of the PD-1 + primary B cells was more than seven times that of the PD-1 − primary B cells (321.17 ± 11.63 versus 41.98 ± 1.97; Fig. 1f ); and the MFI of the EL4 cells was approximately 12 times that of the B16 cells (1532.70 ± 4.99 versus 130.00 ± 2.55; Supplementary  Fig. 2e ). By contrast, both the PD-1 + and the PD-1 − cells had low MFI after incubation with labelled ABD-PE at 37 °C (Fig. 1e,f and Supplementary Fig. 2e ). These data, together with the data generated at 4 °C, suggest that αPD-1-ABD-PE specifically binds to and penetrates PD-1 + cells and αPD-1 directs the specificity. PD-1 was found to shuttle its binding partners into cells and rapidly complete the transport, on the basis that: 1) the MFI of EL4 cells after the 37 °C incubation with αPD-1-ABD-PE was severalfold higher than that after the 4 °C incubation, and 2) both incubations were for only 30 min. It is worth noting that similar results were observed using primary lymphocytes from both C57BL/6 ( Fig. 1c-f ) and non-obese diabetic (NOD) (Supplementary Figs. 1c-f and 2f-i) mice.
To establish the role of PD-1 in the binding and internalization of αPD-1-ABD-PE to PD-1 + cells, we performed a competitivebinding assay with a fusion protein 27 of ligand 1 of PD-1 and a human immunoglobulin G (IgG) Fc domain (PD-L1-Fc) ( Fig. 1g and Supplementary Fig. 3 ). We found that concurrent incubation of αPD-1-ABD-PE and PD-L1-Fc with PD-1 + cells abolished the binding and internalization of αPD-1-ABD-PE into PD-1 + cells. Specifically, in the presence of PD-L1-Fc, the MFI of EL4 cells after the concurrent incubation at 4 °C was approximately oneeighth the MFI of cells incubated with αPD-1-ABD-PE alone (74.58 ± 0.44 versus 583.80 ± 6.76, P < 0.0001; Fig. 1g ); and at 37 °C, the MFI resulting from the concurrent incubation was approximately 1/25 that from the single incubation (74.52 ± 0.63 versus 1895.00 ± 34.82, P < 0.0001; Fig. 1g ). These data corroborate our finding that the binding and internalization of αPD-1-ABD-PE into PD-1 + cells were directed by PD-1. Interestingly, when EL4 cells were pre-incubated with αPD-1-ABD-PE at 37 °C for 30 min before PD-L1-Fc was added to the mixture, PD-L1-Fc only partially decreased the MFI of the EL4 cells, from 1895.00 ± 34.82 to 1320.00 ± 120.30 (Fig. 1g ). The partial decrease may be because the PD-L1-Fc displaced surface-bound αPD-1-ABD-PE, but some αPD-1-ABD-PE had entered the EL4 cells before the addition of PD-L1-Fc and, consequently, could not be displaced by PD-L1-Fc. This observation provides evidence that αPD-1-ABD-PE enters PD-1 + cells. This conclusion regarding PD-1-mediated internalization is likely to hold for PD-1 + cells of different types and origins, since the results are consistent between PD-1 + primary T and B cells, and between cells collected from C57BL/6 and NOD mice ( Supplementary Fig. 3 ).
αPD-1-ABD-PE specifically depletes PD-1 + cells both in vitro and in vivo.
In vitro, αPD-1-ABD-PE was found to be at least 100 times more cytotoxic to PD-1 + primary lymphocytes than to PD-1 − primary lymphocytes: the half-maximal inhibitory concentration (IC 50 ) of αPD-1-ABD-PE for PD-1 + primary T cells was 0.43 nM (95% CI = 0.270-0.69 nM), whereas αPD-1-ABD-PE did not show detectable cytotoxicity towards PD-1 − primary T cells up to 100 nM ( Fig. 2a ); the IC 50 of αPD-1-ABD-PE for PD-1 + primary B cells was 0.47 nM (95% CI = 0.34-0.63 nM), whereas αPD-1-ABD-PE did not show toxicity towards PD-1 − primary B cells up to 100 nM ( Fig. 2b) . A control mixture of αPD-1 and ABD-PE did not show cytotoxicity to either PD-1 + or PD-1 − primary lymphocytes up to 100 nm ( Fig. 2a,b ). The large difference in cytoxicities of αPD-1-ABD-PE and the control mixture indicated that the cytotoxicity of αPD-1-ABD-PE is dependent on a contiguous linkage between αPD-1 and ABD-PE. Similar results were observed with primary lymphocytes from both C57BL/6 ( Fig. 2a ,b) and NOD mice ( Supplementary Fig. 4a,b )
To pinpoint the role of αPD-1 in the selective cytotoxicity of αPD-1-ABD-PE to PD-1 + cells, we generated a PD-1 knockout EL4 cell line (PD-1 − EL4) using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) ( Supplementary Fig. 4c ). We found that αPD-1-ABD-PE was more than 1,000 times more toxic to wild-type EL4 cells than to PD-1 − EL4 cells (IC 50 = 0.64 nM, 95% CI = 0.49-0.83 nM versus IC 50 = 1,120 nM, 95% CI = 702.7-1,773.0 nM; Fig. 2c ). By contrast, a control mixture of αPD-1 and ABD-PE showed little or no cytotoxicity towards both cell lines (IC 50 = 590 nM, 95% CI = 458.7-760.6 nM for wild-type EL4 cells; IC 50 = 1,060 nM, 95% CI = 747.7-1,514.0 nM for PD-1 − EL4 cells). Together, these results point to a clear role of PD-1 in the PD-1 + cell-selective toxicity of αPD-1-ABD-PE.
αPD-1-ABD-PE was also found to effectively deplete PD-1 + cells in vivo. Specifically, a single dose of αPD-1-ABD-PE reduced the fraction of adoptively transferred EL4 cells among circulating lymphocytes in hosts to 2.86 ± 0.46%, whereas mice treated with the mixture of αPD-1 and ABD-PE had an unchanged EL4 cell fraction compared with PBS-treated mice (14.93 ± 1.36% versus 14.37 ± 1.60%; Fig. 2d ). The radically different cell depletion results between αPD-1-ABD-PE and the control mixture again confirm the importance of the linkage between αPD-1 and ABD-PE. ABD increases the plasma exposure of αPD-1-ABD-PE. We also examined the function of ABD in αPD-1-ABD-PE. Native PAGE analysis showed a clear association of αPD-1-ABD-PE with mouse serum albumin (MSA, Fig. 3a ) and human serum albumin (HSA, Fig. 3b ). By contrast, αPD-1-PE did not associate with either MSA or HSA. These data suggest that the ABD component of αPD-1-ABD-PE retains its albumin-binding capacity, and that the interaction between αPD-1-ABD-PE and albumin are dependent on the presence of the ABD. Next, we examined the pharmacokinetics of αPD-1-ABD-PE and αPD-1-PE after intraperitoneal injection of 5.0 nmol of protein per mouse ( Fig. 3c ). A non-compartmental analysis shows that αPD-1-ABD-PE has a systemic clearance (CL) approximately 1/30 that of αPD-1-PE (0.14 ± 0.01 ml h −1 versus 4.05 ± 0.02 ml h −1 ), resulting in 30 times higher plasma exposure (area under curve, AUC 0-t ). αPD-1-ABD-PE has a 57-fold longer terminal half-life (t 1/2 ) than αPD-1-PE (76.35 ± 9.13 h versus 1.34 ± 0.02 h). αPD-1-ABD-PE also has better volume distribution (V d ) than αPD-1-PE (Table 1 ). These data indicate that the ABD in αPD-1-ABD-PE improved the pharmacokinetics of the construct, which was expected to benefit the efficacy of αPD-1-ABD-PE, since poor pharmacokinetics are reported to limit the efficacy of previously developed immunotoxins 38 .
αPD-1-ABD-PE delays the onset of T1D. Female NOD mice are prone to developing T1D 39 . We treated 12-week-old female NOD mice that did not yet show hyperglycaemia with weekly injections of either: (1) αPD-1-ABD-PE, (2) PBS, or (3) a mixture of αPD-1 and ABD-PE. αPD-1-ABD-PE treatment markedly delayed the onset of T1D (indicated by hyperglycaemia) compared with PBS or the control mixture. The median T1D-free survival time of the PBS-treated mice and the control mixture-treated mice were both 49 days after treatment (P = 0.3480 between the two treatments). By contrast, the median T1D-free survival time of the αPD-1-ABD-PE-treated mice was 119 days after treatment ( Fig. 4a ; P = 0.0180 versus PBS treatment). We also examined the T1D-delaying effect of αPD-1-ABD-PE in a pathologically accelerated T1D model. Ten-week-old female NOD mice were pre-treated with cyclophosphamide to expedite the onset of T1D, which is due to the ability of cyclophosphamide to ablate regulatory T-cells (T reg ) in NOD mice 40 . Mice pre-treated with cyclophosphamide were subsequently treated with either: (1) αPD-1-ABD-PE, (2) PBS, or (3) a mixture of αPD-1 and ABD-PE. Both PBS-treated and mixture control-treated mice had a very short median T1D-free survival time of 13 days. By contrast, the αPD-1-ABD-PE-treated mice had a significantly longer median T1D-free survival time of 33 days ( Fig. 4b ; P = 0.0068 versus PBS; P = 0.0094 versus the mixture control). These data, together with the spontaneous T1D data, demonstrate that αPD-1-ABD-PE inhibits the development of T1D.
Since the pancreatic infiltrations of PD-1 + cells and lymphocytes, especially CD4 lymphocytes, parallel the progression of T1D in NOD mice 25, 39, 41 , we investigated whether αPD-1-ABD-PE treatment would diminish PD-1 + cell and lymphocyte infiltrations in the pancreas ( Supplementary Fig. 5 ). Indeed, even a single dose of αPD-1-ABD-PE significantly reduced the fraction of PD-1 + cells in pancreas as compared with PBS (0.17 ± 0.02% versus 0.39 ± 0.03%, P = 0.0002; Fig. 4c ). By contrast, the control mixture did not reduce the fraction of PD-1 + cells in the pancreas (0.56 ± 0.07%, P = 0.052). The level of PD-1 expression (MFI) in PD-1 + cells that survived the αPD-1-ABD-PE treatment was slightly but significantly lower (2,132.17 ± 16.82, P = 0.025) than in the PD-1 + surviving the PBS treatment (2,187.00 ± 12.12, Supplementary Fig. 6a ). There was no significant difference in PD-1 expression between the cells from the PBS and the control mixture treatments. These results may be due to preferential targeting of αPD-1-ABD-PE to PD-1 high cells over PD-1 low cells. Further, αPD-1-ABD-PE treatment also significantly reduced the fractions of PD-1 + CD4 T cells and PD-1 + CD8 T cells in the pancreas as compared with PBS (P = 0.0007 and 0.0002, respectively; Fig. 4d,e ). By contrast, the control mixture did not reduce the fractions of these two populations of PD-1 + lymphocytes, and slightly increased the PD-1 + CD4 T-cell fraction. These results also revealed that PD-1 + CD4 T cells are the major PD-1 + cells in the pancreases of the PBS-treated mice, accounting for approximately 75% of the PD-1 + cells. There was no detectable population of PD-1 + T reg cells or PD-1 + B cells in the pancreases ( Supplementary Fig. 6b ,c). The αPD-1-ABD-PE treatment also reduced total CD4 and CD8 cells but not B cells in the pancreases, as compared with PBS (P = 0.0002, 0.0008 and 0.119, respectively; Fig. 4f -h). The control mixture, as expected, did not affect these cells. Thus, αPD-1-ABD-PE reduced the fractions of total PD-1 + cells, PD-1 + CD4 T cells, PD-1 + CD8 T cells, CD4 T cells, and CD8 T cells in the pancreases of treated mice, which might contribute to its marked delaying effect on the onset of T1D. Among these populations, PD-1 + CD4 T cells are likely to be a decisive factor, given that they represent a major fraction of the PD-1 + cells (75%) and their numbers were reduced by approximately 3 times after the αPD-1-ABD-PE treatment. We also attempted to examine PD-1 + T cells and PD-1 + B cells in blood, spleens, and lymph nodes of these treated mice. However, these cells did not form distinguishable populations, probably owing to their scarcity ( Supplementary  Fig. 6d -i). In other words, the baseline numbers of PD-1 + cells in blood and peripheral lymphatic organs are very low. Because of this result, we do not expect the total T cell and B cell numbers in these organs to be altered by αPD-1-ABD-PE treatments.
In addition to the pancreatic infiltration of lymphocytes, there were other data suggesting that αPD-1-ABD-PE selectively depletes autoreactive PD-1 + cells in NOD mice ( Fig. 4i ). PD-1 antibody usually accelerates T1D progression in NOD mice because it allows autoreactive PD-1 + cells to proliferate 19, [24] [25] [26] [27] . In this study, αPD-1 accelerated the onset of T1D in NOD mice that were pretreated with PBS and the mixture control: the median T1D-free survivals were 15 and 13 days, respectively ( Fig. 4i ). By contrast, the T1D exacerbating effect of αPD-1 diminished in NOD mice pre-treated with αPD-1-ABD-PE; these mice did not show hyperglycaemia even at the end of the experiment (26 days after the treatment). Because autoreactive PD-1 + cells are the primary effector cells that cause T1D and execute the exacerbating effect of αPD-1, the diminished effect of αPD-1 in the mice pre-treated with αPD-1-ABD-PE suggests that there is a reduction of autoreactive PD-1 + cells in these mice.
αPD-1-ABD-PE treated mice recover from EAE. C57BL/6 mice immunized with a peptide of myelin oligodendrocyte glycoprotein (MOG ) in adjuvant develop experimental autoimmune encephalomyelitis (EAE), a monophasic clinical disease from which mice rarely recover 42, 43 . To test whether αPD-1-ABD-PE modulates EAE, C57BL/6 mice with EAE were treated with either: (1) αPD-1-ABD-PE, (2) PBS, or (3) a mixture of αPD-1 and ABD-PE. Before the treatments, all the mice had paralysed hind limbs, a sign of severe EAE (clinical score 3.0). All six of the mice treated with αPD-1-ABD-PE recovered from the paralytic diseases after a single dose ( Fig. 5a,b ), but all the mice had an EAE clinical score of 1.0 at the end of the study. In another replicate study, two of five mice treated with αPD-1-ABD-PE showed no clinical sign of EAE (fully recovered) at the end of the study (clinical score 0, Supplementary Fig. 7a ), whereas the other three mice had clinical scores of 1.0. By contrast, none of the paralysed mice that received PBS or the control mixture treatment recovered. Instead, their EAE steadily worsened. The EAE scores of all mice in these two groups reached 4.0 by the end of this study. Indeed, from day 5 after treatment, the mean clinical score of the αPD-1-ABD-PE treatment group was consistently and significantly lower than the scores of the PBS-and the control mixture-treated groups. It is important to note that mice in the three groups developed EAE with the same kinetics before the various treatments were applied ( Fig. 5a ): there was no significant difference in mean EAE scores among the three groups until day 19 after EAE induction (P > 0.05 for all the monitored time points). At that time, some mice had received treatments, and the treatment had started to alter their EAE progression. The identical kinetics of EAE development among the three groups before the treatments, conversely, underscores the power of αPD-1-ABD-PE to interfere with and reverse the disease progression. We investigated whether αPD-1-ABD-PE treatment reduced the infiltrations of PD-1 + cells and lymphocytes into the central nervous system (CNS) of the mice with EAE. The presence of these cells, especially CD4 cells, in the CNS has been linked to EAE progression 18, 19, 44 . Even a single dose of αPD-1-ABD-PE reduced the fraction of PD-1 + cells in the CNS to 20% that of the group treated with PBS ( Fig. 5c ; 0.19 ± 0.03 % versus 1.07 ± 0.09 %, P < 0.0001). By contrast, the control mixture of αPD-1 and ABD-PE did not reduce the fraction of PD-1 + cells in the CNS (1.19 ± 0.07 %, P = 0.341). PD-1 + cells collected from the αPD-1-ABD-PE-treated mice also exhibited significantly lower PD-1 expression (1,793.83 ± 11.55, P = 0.0013) 
Fig. 2 | αPD-1-aBD-Pe is selectively toxic to PD-1 + cells in vitro and in vivo. a,
The relative viability of PD-1 + and PD-1 − primary T cells from C57BL/6 mice after the cells were incubated with αPD-1-ABD-PE or a control mixture of αPD-1 and ABD-PE for 72 h. Viabilities are shown as mean ± s.d. at different concentrations of αPD-1-ABD-PE and control mixture. The viability data for PD-1 + primary T cells with αPD-1-ABD-PE treatment are fitted to a sigmoidal dose-response model and the IC 50 was obtained (n = 6 biologically independent samples). b, The relative viability of PD-1 + and PD-1 − primary B cells from C57BL/6 mice after the cells were incubated with αPD-1-ABD-PE or a control mixture of αPD-1 and ABD-PE for 72 h. Viabilities are shown as mean ± s.d. at different concentrations of αPD-1-ABD-PE and control mixture (n = 6 biologically independent samples). c, The relative viability of wild-type EL4 and PD-1 − EL4 cells after they were incubated with αPD-1-ABD-PE or a control mixture of αPD-1 and ABD-PE for 72 h. Viabilities are shown as mean ± s.d. at different concentrations of αPD-1-ABD-PE and control mixture and fitted to a sigmoidal dose-response model (n = 6 biologically independent samples). d, The fractions of transferred EL4 cells among lymphocytes collected from mice 72 h after the mice were treated with αPD-1-ABD-PE, a control mixture of αPD-1 and ABD-PE, or PBS. Data are mean ± s.d. (n = 3 mice). All studies described in this figure were repeated twice with similar results. Data from one repeat are shown here.
than PD-1 + cells from the PBS-treated mice (1,877.83 ± 15.2, Supplementary Fig. 7b ). Interestingly, the cells collected from the mice treated with control mixture showed slightly lower PD-1 expression (1836.00 ± 8.14) than those treated with PBS. Further, treatment with αPD-1-ABD-PE significantly reduced the fractions of PD-1 + CD4 T cells and PD-1 + CD8 T cells in the CNS as compared with PBS (P < 0.0001 and P = 0.003 for CD4 and CD8 T cells, respectively; Fig. 5d ,e). By contrast, treatment with control mixture did not reduce the fractions of these PD-1 + lymphocytes in the CNS. PD-1 + CD4 T cells account for the vast majority of PD-1 + cells in the CNS of the mice with EAE (98.1% in the PBS-treated mice). There was no detectable population of PD-1 + T reg cells or PD-1 + B cells in the CNS ( Supplementary Fig. 7c,d) . The αPD-1-ABD-PE treatment also reduced total numbers of CD4 T cells and CD8 T cells, but not of B cells in the CNS, as compared with PBS (P < 0.0001, 0.0001 and 0.567, respectively; Fig. 5f-h) . The control mixture, as expected, did not affect these cells. Finally, we compared the effects of the three treatments on the ratios of T reg cells and CD4 T cells that are specific for MOG [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] (GWYRPPFSRVVH) in the CNS. This MOG-specific clone is the main autoreactive effector T cell clone in this EAE model 45 . We found that αPD-1-ABD-PE treatment increased this ratio by approximately fourfold, as compared with PBS treatment (P < 0.0001, Fig. 5i ). The T reg fraction in the CNS was not changed after the αPD-1-ABD-PE treatment ( Supplementary  Fig. 7e ) but the fraction of MOG-specific CD4 T cells decreased ( Supplementary Fig. 7f ). The control mixture did not significantly alter the ratio (Fig. 5i ). Taken together, these results show that the αPD-1-ABD-PE treatment reduced infiltration of PD-1 + cells and T cells into the CNS of treated mice and the treatment increased the T reg to effector T cell ratio, indicating immune tolerance.
We also examined, but did not detect, PD-1 + T cells and PD-1 + B cells in blood, spleen and lymph nodes of treated EAE mice ( Supplementary Fig. 7g -l).
αPD-1-ABD-PE does not compromise normal adaptive immune responses.
The αPD-1-ABD-PE treatment did not cause lymphopenia, which is often associated with therapeutics for autoimmune diseases 6, [9] [10] [11] [12] 46 . We compared the B220 + , CD4 + and CD8 + lymphocytes in blood and spleens of C57BL/6 mice ( Fig. 6a ) after they received one dose of: (1) αPD-1-ABD-PE, (2) PBS, (3) a mixture of αPD-1 and ABD-PE, or (4) cyclophosphamide (CP). CP is a non-specific immunosuppressant used here as a positive control for immune suppression. αPD-1-ABD-PE did not reduce the numbers of these three lymphocyte subpopulations in comparison to the PBS treatment ( Fig. 6a,b) . Similarly, the mixture control did not affect the proportions of these lymphocyte subpopulations. However, cyclophosphamide reduced the numbers of B220 + , CD4 + and CD8 + lymphocytes in blood by 70.1%, 69.5% and 75.6%, respectively (P < 0.0001, P = 0.0002 and P = 0.0002, respectively; Fig. 6a ). CP reduced the numbers of B220 + , CD4 + and CD8 + lymphocytes in spleens by 46.0%, 76.0% and 70.1%, respectively (P = 0.0002, P < 0.0001 and P < 0.0001, respectively; Fig. 6b ). These findings were reproducible in NOD mice ( Supplementary Fig. 8a,b) .
The αPD-1-ABD-PE treatment did not affect antibody responses in treated mice. We treated C57BL/6 and NOD mice with one dose of: (1) αPD-1-ABD-PE, (2) PBS, (3) a mixture of αPD-1 and ABD-PE, or (4) CP. Two days after this treatment, the mice were immunized with 2,4-dinitrophenyl-Ficoll (DNP-Ficoll), a T cell-independent antigen 47 . We found that both the αPD-1-ABD-PE-treated mice and the control mixture-treated mice developed the same level of anti-DNP responses as the PBS-treated mice ( Fig. 6b and Supplementary Fig. 8c-f ). However, CP-treated mice developed weaker anti-DNP responses. These findings were reproduced in both C57BL/6 and NOD mice. Of note, similar results were observed in mice that were treated with five doses of each treatment ( Supplementary Fig. 8g,h) .
The αPD-1-ABD-PE treatment did not affect cytotoxic T lymphocyte (CTL) responses. We treated C57BL/6 and NOD mice with one dose of: (1) αPD-1-ABD-PE, (2) PBS, (3) a mixture of αPD-1 and ABD-PE, or (4) CP. Two days after this treatment, NOD mice were immunized with TYQRTRALV, a CTL-epitope vaccine matched to the major histocompatibility complex (MHC) class I background of NOD mice. At the same time, treated C57BL/6 mice were immunized with SIINFEKL, a CTL vaccine that was derived from ovalbumin (residues 257-264) and matched with the MHC class I background of C57BL/6 mice. Mice treated with αPD-1-ABD-PE, control mixture or PBS all developed similar levels of mice; unpaired two-sided t-test). i, Diabetes-free survival of NOD mice treated first with αPD-1-ABD-PE, a control mixture of αPD-1 and ABD-PE, or PBS, and then with αPD-1 (full IgG) (n = 5 mice; unpaired two-sided t-test) The survival of mice treated with αPD-1-ABD-PE is significantly different to that of mice treated with PBS or the control mixture treated (P = 0.0494 or P = 0.0018, respectively). All studies described in this figure were repeated twice with similar results. Data from one repeat are shown here.
CTL responses (Fig. 6c ). By contrast, C57BL/6 and NOD mice treated with CP developed weaker CTL responses as compared with those treated with PBS (P = 0.011 and P = 0.026 for C57BL/6 and NOD mice, respectively). Together, these data show that αPD-1-ABD-PE treatment did not significantly alter the ability of the treated mice to mount antibody and/or CTL responses.
Discussion
The results of this study show that αPD-1-ABD-PE exhibits specific toxicity towards PD-1 + B and PD-1 + T cells. Depletion of PD-1 + cells, enabled by αPD-1-ABD-PE, ameliorates autoimmunity in multiple disease models that are different in pathogenesis. Furthermore, application of PD-1 + cell depletion does not cause adaptive immune deficiency. In a chronic EAE model, even a single dose of αPD-1-ABD-PE fully restored mobility in mice that were paralysed by EAE, a rarely achieved therapeutic outcome. In addition, the single dose of αPD-1-ABD-PE significantly reduced numbers of PD-1 + cells, T lymphocytes and autoreactive lymphocytes in the CNS of the treated mice. Current therapies for MS are termed disease-modifying therapies because they only delay disease progression and do not reverse or cure (or cure) the disease 6, 11 . The noted efficacy of PD-1 + cell depletion may be able to fill an important clinical gap in MS treatment. In a spontaneous model of T1D and in two accelerated-T1D models (CP treatment and αPD-1 IgG treatment), PD-1 + cell depletion markedly delayed T1D onset. Under the studied conditions, T1D eventually developed in the spontaneous and the CP-accelerated models. Nevertheless, it is possible that the efficacy of PD-1 + cell depletion could be further boosted by regimens that are optimized for the pharmacokinetics-pharmacodynamics of αPD-1-ABD-PE. The improved efficacy may allow the depletion to completely prevent T1D. This possibility is supported by the observed broad impact of a single dose of αPD-1-ABD-PE on immune cells in pancreases; the single dose decreases the fractions of PD-1 + CD4 T cells and PD-1 + CD8 T cells, as well as total CD4 and CD8 T cells, a global attenuation of the inflammation in pancreases. PD-1 + cell depletion may also help to reverse T1D in combination with β-cell compensation therapy 2, 4 . It is notable that PD-1 + cell depletion delayed the onset of CP-induced T1D. This observation implies first that PD-1 + cells may be the primary effector cells in autoimmunity driven by T reg deficiency, since CP causes T reg deficiency 40 . Second, it suggests that PD1 + cell depletion may be able to resolve the autoimmunity that does not originate from the abnormality of the PD-1 checkpoint. Together, PD-1 + cell depletion is effective against EAE and T1D, two T cell-driven autoimmune disease models; PD-1 + CD4 T cells appeared to be the major pathogenic cell population in the two models, and both responded well to PD-1 + cell depletion.
PD-1 + cell depletion is likely to be effective against B cell-mediated autoimmune diseases. First, such autoimmune diseases, like SLE, depend on not only B cells but also CD4 T cells such as follicular helper T (T fh ) cells and extrafollicular helper T (T h ) cells.
These CD4 T cells facilitate the formation of germinal centre, the maturation of B cells, and antibody production 48 . Our results also show that PD-1 + cell depletion diminished both PD-1 + CD4 T cells and total CD4 T cells ( Figs. 4 and 5 ). Further, our results confirm and NOD mice treated with one dose of αPD-1-ABD-PE, a control mixture of αPD-1 and ABD-PE, PBS, or CP. Data represent mean ± s.d. of the number of IFN-γ-positive spots resulting from 500,000 splenocytes collected from the treated mice (n = 6 mice; unpaired two-sided t-test; C57BL/6 mice: NS, not significant, P = 0.9314 unpaired t-test; NOD mice: NS, not significant, P = 0.9429). All studies described in this figure were repeated at least twice with similar results. Data from one repeat are shown here.
that αPD-1-ABD-PE is able to specifically bind to, penetrate, and eliminate PD-1 + primary B cells. Finally, PD-1 knockout mice show increased IgG production and eventually develop lupus-like symptoms 48 . One interpretation for this observation is that activated autoreactive cells in the mice escape the PD-1 immune checkpoint and cause the lupus-like symptoms, since these cells do not express PD-1. By contrast, activated autoreactive cells are PD-1 + in wildtype mice, and hence inhibited by the checkpoint. In mice with SLE, the checkpoint fails to suppress activated autoreactive cells. However, it is possible to utilize PD-1 as a biomarker to identify and deplete the cells and rescue autoimmune destruction in the mice with SLE. In sum, PD-1 + cell depletion impacts both PD-1 + B cells and PD-1 + CD4 T cells and is likely to alleviate B-cell mediated autoimmune diseases. PD-1 + cell depletion preserves normal adaptive immunity, which sharply contrasts with the generalized immune deficiency caused by currently available immune suppressants 6, [9] [10] [11] [12] 46 . It is acknowledged that PD-1 + cell depletion could diminish non-autoreactive PD-1 + lymphocytes, including PD-1 + effector cells and T reg cells 49 . However, we feel that this represents only a theoretical concern. First, PD-1 + effector cells can be replenished from naive lymphocytes upon immune stimulation, as lymphocyte repertoires are not impaired by PD-1 + cell depletion. Second, PD-1 + cells are scarce and barely detectable in blood and peripheral lymphatic organs in mice with T1D and EAE-and they are relatively concentrated in inflamed organs (Figs. 4 and 5 and Supplementary Figs. 6-7) . This intrinsic distribution of PD-1 + cells helps to alleviate the negative impact of PD-1 + cell depletion on non-autoreactive lymphocytes. Third, the finding that PD-1 + cell depletion preserves adaptive immunity argues against the theoretical concern; mice in which PD-1 + cells were depleted were able to mount normal immune responses as soon as two days after the depletion. There are further arguments supporting the depletion of PD-1 + cells in autoimmune diseases. In the context of autoimmune diseases, the immune system is, overall, tilted towards autoimmunity rather than immune tolerance or anergy 50 . Autoreactive PD-1 + lymphocytes outweigh their non-autoreactive counterparts, including PD-1 + T reg cells 49 in terms of impact to the well-being of patients. Therefore, it is arguably beneficial to purge all PD-1 + cells, reprogramme the immune system, and restore immune homoeostasis. PD-1 + cell depletion, indeed, resembles systemic γ-irradiation or lymphocyte depletion, which have both been used to reprogramme the immune system 51 . Yet, PD-1 + cell depletion is a much more focused approach. One observation that supports this idea of purging PD-1 + cells is that the αPD-1-ABD-PE treatment, while reducing PD-1 + CD4 T cells, PD-1 + CD8 T cells, and autoreactive T cells in pancreases of NOD mice and the CNS of mice with EAE, did not diminish T reg cells in these organs. Indeed, the depletion increased the ratios of T reg cells to autoreactive cells in the CNS, which favours the treatment of autoimmune diseases.
Targeted depletion of PD-1 + cells, enabled by αPD-1-ABD-PE, exhibits three appealing features as a new therapeutic option for autoimmune diseases. First, the depletion has a straightforward and robust mechanism. It relies on a simple cytotoxic mechanism to kill PD-1 + cells; yet, a single administration can suppress autoimmunity completely, enabling, for example, paralysed mice to regain normal gait. Second, the depletion can suppress both T cell-and B cell-mediated autoimmunity in an autoimmune disease. It also has potential to treat autoimmune diseases driven primarily by T cells or B cells. Third, the PD-1 + cell depletion does not cause longterm immune deficiency. Although the depletion can also affect non-autoreactive PD-1 + cells and may affect the healthy immunity during the treatment, the immunity appears to recover very quickly because of preservation of naive cells. Indeed, as soon as two days after the depletion, αPD-1-ABD-PE-treated mice were able to mount the same level of adaptive responses as PBS-treated mice. Thus, PD-1 + cell depletion did not have a long-term impact on healthy immunity. In summary, targeted depletion of PD-1 + cells is an effective and broadly applicable approach to treating autoimmune diseases without jeopardizing healthy immunity.
Methods
Mice and cell lines. Female C57BL/6 mice were purchased from The Jackson Laboratory. Female NOD mice were purchased from The Jackson Laboratory and bred in-house. Animal studies were conducted following a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Utah. The group sizes of mice were determined and approved by the regulatory authorities for animal welfare after a balanced consideration of statistical and scientific needs and ethical aspects. All procedures related to animal studies are in compliance with relevant ethical regulations on animal research at the University of Utah. EL4 and B16-F10 cell lines were purchased from ATCC and maintained in DMEM medium with 10% FBS.
Antibodies. Capture anti-mouse interferon-γ (IFN-γ) monoclonal antibody (clone R4-6A2) and biotinylated, detection anti-mouse IFN-γ monoclonal antibody (clone XMG1.2-biotin) were purchased from BioLegend. Peroxidaseconjugated AffiniPure Donkey Anti-Mouse lgM and Peroxidase AffiniPure Goat Anti-Mouse IgG (H + L) were purchased from Jackson ImmunoResearch. Anti-mouse CD-3 antibody (clone 145-2C11) was purchased from BioXCell. FITC-, PE-, APC-or biotin-conjugated monoclonal antibodies to Foxp3 (clone MF-14), B220 (clone RA3-6B2), CD4 (clone GK1.5), and CD8 (clone 53-6.7) were purchased from BioLegend.
Generation of expression vectors for recombinant proteins. Genes encoding
αPD-1 (scFv), PE, or ABD-PE were synthesized by Biomatik. All the genes were inserted into the pET25b ( + ) vector at the BseRI restriction sites. The configuration of the αPD-1 (scFv) was NH 2 -V H -linker-V L -COOH, where V H and V L were the variable regions of the αPD-1 heavy chain and the αPD-1 light chain, respectively. Two mutations were introduced into αPD-1, V H R45C and V L G104C. The linker in αPD-1 was (GGGGS) 3 . The linker was also inserted between the ABD domain and the PE domain of ABD-PE. The coding genes of αPD-1-ABD-PE and αPD-1-PE were generated by fusing the synthesized genes together using a previously described protocol 52, 53 . Meanwhile, a gene encoding the linker was inserted between the genes for αPD-1 and ABD-PE, and between the genes for αPD-1 and PE. The linker gene was generated by annealing the sense and antisense oligonucleotides of the gene (Eurofins Genomics). A hexahistidine tag (HisTag) was added at the N-terminus of αPD-1-ABD-PE and the control proteins to facilitate their purification; the GGGGS linker was inserted between the HisTag and the proteins. Accordingly, the coding gene of the HisTag was also fused to the coding genes of these proteins. The sizes of the final constructs were confirmed by agarose gel electrophoresis after cleavage from the pET25b(+) vector by double digestion with BamHI and XbaI. The sequences of the genes were verified by DNA sequencing (Genewiz).
Protein expression and purification. The pET25b(+) vectors harbouring coding sequences for αPD-1-ABD-PE, αPD-1, ABD-PE, and αPD-1-PE were transferred into competent Shuffle T7 E. coli (New England Biolabs). These transformed E. coli were cultured in LB broth at 32 °C until the absorbance at 595 nm (A 595 nm ) of the culture reached 0.6. At that point, the cultured cells were induced with 1 mM final concentration IPTG (Gold Biotechnology) for protein expression and incubated for a further 18 h.
The cultured E. coli were collected by centrifugation at 4,700 r.p.m. for 30 min. The collected cells were lysed by sonication using a 4 min pulse. The cell samples were kept on ice during sonication, and 1 mM PMSF (Gold Biotechnology) was added to the cell lysate to inhibit protein degradation. After sonication, the supernatant of the cell lysate was collected by centrifuging the lysed samples at 20,000g for 1 h. Next, imidazole powder was added to the supernatant to reach a final imidazole concentration of 20 mM. At the same time, HisPur Ni-NTA resin (Thermo Fisher Scientific) was equilibrated with 10 mM imidazole in PBS. The equilibrated resin was then incubated with the supernatant for 1 h at 4 °C on a rotator mixer. After the incubation, the mixture was loaded on a column, and the impurities and endotoxins were removed by washing the column with 60 mM imidazole that contained 1% Triton X-114. The wash was repeated until protein concentrations in the eluent were very low (A 280 nm < 0.01). The use of 1% Triton X-114 for endotoxin removal was described previously 54 . After this purification step, Triton X-114 was removed by washing the column with 50 column volumes of 60 mM imidazole. Finally, the desired proteins were eluted from the column with 300 mM imidazole in PBS (pH = 8). Imidazole was removed using PD-10 desalting columns (GE Healthcare Life Sciences). The purity and residual endotoxin level of the resulting proteins were analysed by SDS-PAGE and PYROGENT single-test vials (Lonza).
SDS-PAGE analysis of proteins.
Five micrograms of αPD-1, ABD-PE, αPD-1-PE, and αPD-1-ABD-PE were first reduced with 2-mercaptoethanol and denatured by heating at 95 °C for 5 min. Then, these denatured samples were analysed by 4-15% gradient SDS-PAGE. After electrophoresis, the gel was stained with Coomassie brilliant blue and photographed using an Alpha Innotech Fluorchem FC2 gelimaging system. The image was processed by adjusting the brightness and contrast for the entire image using GNU Image Manipulation Program (GIMP).
Determination of the binding affinity of αPD-1-ABD-PE to EL4 cells.
Onemillion EL4 cells were incubated with Alexa Fluor 647-labelled αPD-1-ABD-PE and anti-PD-1 IgG at a series of different concentrations at 4 °C for 30 min. Then, the EL4 cells were analysed by flow cytometry for PD-1 + EL4 cell fractions. The fraction of PD-1 + EL4 cells was plotted against protein concentration and K d values were obtained by fitting the curve using the sigmoidal dose-response model in GraphPad v.5. The half-maximal response value (EC 50 ) was used as the K d value 55 . GraphPad was used to calculate the 95% confidence intervals (95% CI).
Generation of PD-1 + primary T cells.
Mouse splenocytes were collected and cultured in 96-well plates at 2 × 10 6 cells per ml in complete RPMI-1640. Then, concanavalin A (Con A) (InvivoGen) was added to the culture at 6.25 µg ml −1 to stimulate PD-1 expression on primary T cells 14 . After 72 h stimulation, cells were collected. PD-1 − primary T cells were naive splenocytes cultured in the complete RPMI-1640 media without Con A for 72 h. These primary T cells were stained with PE-conjugated CD3 antibody for flow cytometry analysis.
Generation of PD-1 + primary B cells.
Mouse splenocytes were collected and cultured in 96-well plates at 2 × 10 6 cells per ml in complete RPMI-1640. Then, 10 µg ml −1 AffiniPure F(ab′) 2 fragment of goat anti-mouse IgM, µ-chain specific (Jackson ImmunoResearch, code 115-006-020) was added to the culture to stimulate PD-1 expression on primary B cells 14 . After 72 h stimulation, the cells were collected. PD-1 − primary B cells were naive splenocytes cultured in the complete RPMI-1640 media without anti-IgM for 72 h. These primary B cells were stained with PE-conjugated B220 antibody for flow cytometry analysis.
Evaluation of cell binding and endocytosis. αPD-1-ABD-PE or ABD-PE was first labelled with Alexa Fluor 647 NHS Ester (Thermo Fisher Scientific). The labelled αPD-1-ABD-PE or ABD-PE (100 nM) was incubated with 0.5 × 10 6 cells at 4 °C or 37 °C in FACS buffer (PBS with 0.1% fetal bovine serum (FBS)) for 30 min. After the incubation, unbound proteins were removed by centrifugation (350g for 5 min). Finally, the MFI of the incubation mixture was determined by flow cytometry with a BD FACSCanto Analyzer (BD Biosciences).
Specifically, for primary B cells, the MFI values of B-cell populations were analysed. B-cell populations were identified by staining the cell mixture with PE-labelled B220 antibody.
For primary T cells, the MFI values of T-cell populations were analysed. T-cell populations were identified by staining the cell mixture with PE-labelled CD3 antibody.
Binding inhibition study with PD-L1-Fc. A fusion protein containing PD-L1
and human Fc (PD-L1-Fc; Sino Biological, 50010-M03H) was used to compete for surface PD-1 binding with αPD-1-ABD-PE. For binding inhibition studies, 500 nm PD-L1-Fc and 100 nm Alexa Fluor 647-labelled αPD-1-ABD-PE were incubated with 0.5 × 10 6 cells for 30 min at 4 °C or 37 °C. Then, unbound proteins were washed away by centrifugation (350g for 5 min) in FACS buffer. The cells were analysed by flow cytometry with a BD FACSCanto Analyzer (BD Biosciences). Human IgG at 500 nM was used as the control for PD-L1-Fc.
For removal of surface-bound αPD-1-ABD-PE, Alexa Fluor 647-labelled αPD-1-ABD-PE was first incubated with 0.5 × 10 6 cells for 30 min at 37 °C. PD-L1-Fc was then added to a final concentration of 500 nM. The incubation mixtures were maintained at 4 °C for an additional 30 min before unbound proteins were washed away by centrifugation (350g for 5 min) in FACS buffer. The cells were analysed by flow cytometry with a BD FACSCanto Analyzer (BD Biosciences).
Generation of PD-1 − EL4 cell line.
We chose a single guide RNA (sgRNA) sequence in exon 2 of the mouse Pdcd1 (NC_000067.6) gene that encodes PD-1 on the basis of a previously described algorithm 56 . The sgRNA sequence was CCTTGACACACGGCGCAATGACAGTGGCAT. The protospacer adjacent motif (PAM) was TGG. To target this sgRNA, we used two oligos: 5′-CACCGGACACACGGCGCAATGACAG−3′ and 5′-AAACCTGTCATTGCGCCGTGTGTCC−3′ (Integrated DNA Technologies). The two oligos were annealed and ligated into the lentiviral vector lentiCRISPRv2-mCherry, which was provided by V. Planelles (University of Utah). High-titre lentiviral supernatants were generated as previously described 57 by co-transfection of HEK-293T cells (ATCC) with the packaging plasmids pMD2.G (Addgene 12259) and psPAX2 (Addgene 12260). After EL4 cells were transduced with lentiviral supernatants, the transductants were stained with PE-Cy7-conjugated anti-PD-1 antibody (BioLegend, Clone: RMPI-30) and sorted for mCherry + PD-1 − cells with a FACSAria cell sorter (BD Biosciences) at the Flow Cytometry Core of the University of Utah. The EL4 and HEK-293T cell lines were maintained in DMEM medium with 10% FBS.
Cytotoxicity study. For the cytotoxicity study with PD-1 + primary T cells, naive splenocytes (concentration 2 × 10 6 ml −1 ) were first stimulated with 6.25 µg ml −1 Con A for 24 h. Then, αPD-1-ABD-PE or the control mixture was added to the wells without removing Con A. Two days after adding the proteins, cells were collected. Live cells were stained with trypan blue and counted. The percentage of PD-1 + primary T cells among these live cells was determined by flow cytometry after the live cells were stained with PE-conjugated CD3 antibody (Biolegend), 3 µM DAPI (4′,6-diamidino-2-phenylindole, dilactate) (Biolegend), and Alexa Fluor 647-conjugated PD-1 antibody, which was made in house. Finally, the number of live PD-1 + primary T cells was calculated by multiplying the number of total live cells with the percentage of PD-1 + primary T cells. For the cytotoxicity study, PD-1 − primary T cells (naive splenocytes, 2 × 10 6 ml −1 ), were first cultured in complete RPMI-1640 for 24 h. Then, αPD-1-ABD-PE or the control mixture was added to the culture. Two days later, cells were collected and analysed as described above. The total number of live cells, the percentage of PD-1 − primary T cells and the number of live PD-1 − primary T cells were determined as for PD-1 + primary T cells.
Cell viabilities were calculated for different concentrations of αPD-1-ABD-PE and the control mixture using the equation:
Cell viability (%) = [No. of PD-1 + (or PD-1 − ) T cells in treatment well]/[No. of PD-1 + (or PD-1 − ) T cells in non-treatment well]. The viability data was fitted to a sigmoidal dose-response model to determine IC 50 and 95% CI using GraphPad v.5 (n = 6).
The toxicity study with PD-1 + and PD-1 − primary B cells was performed in the same way as the one with T cells, except that anti-mouse IgM was used to stimulate B cells and PE-conjugated B220 antibody was used to stain B cells.
For cytotoxic studies on EL4 cells and PD-1 − EL4 cells, EL4 cells or PD-1 − EL4 cells (10,000 cells per well) were seeded into 96-well plates. αPD-1-ABD-PE or control mixture was incubated with the cells in 100 μl medium at 37 °C for 72 h. After the incubation, proliferations of these cells was determined using the CellTiter MTS assay (Promega), and the A 490 nm of each treated cell sample was measured. The same measurement was also performed for untreated cells (the live control) and for cells that were treated with 1% Triton X-100 (the dead control). The cell viabilities were calculated for different concentrations of αPD-1-ABD-PE and the control mixture using the following equation: cell viability (%) = (A treated − A dead control )/(A live control − A dead control ), where A treated is A 490 nm of control-or αPD-1-ABD-PE-treated cells, A live control is A 490 nm of the live control, and A dead control is A 490 nm of the dead control (Triton X-100-treated) cells. Viability data was fitted to a sigmoidal dose-response model to determine IC 50 and 95% CI using GraphPad v.5 (n = 6).
In vivo EL4 depletion. Five-million EL4 (PD-1 + ) cells were injected intravenously into the tail of C57BL/6. The injected mice were randomly assigned into three groups. Two hours later, the three groups were treated with a single dose of αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), or PBS intraperitoneally. At 72 h after the treatments, these mice were euthanized, and circulating lymphocytes were collected from them. The cells were stained with Alexa Fluor 647-labelled PD-1 antibody and analysed by flow cytometry with a BD FACSCanto Analyzer to determine the fractions of PD-1 + cells among circulating lymphocytes.
Albumin-binding study. MSA (>96% pure, Sigma) and HSA (>97% pure, Sigma) were dissolved in PBS. αPD-1-ABD-PE (17.4 μg) or αPD-1-PE (15.9 μg) were incubated with 20.0 μg MSA or HSA (1:1 molar ratio) in 20 μl PBS at room temperature for 15 min. After incubation, the samples were analysed by native PAGE. The PAGE gel was stained with Coomassie brilliant blue and photographed using an Alpha Innotech Fluorchem FC2 gel imaging system. The image was processed by adjusting the brightness and contrast of the entire image using GIMP.
For HSA, the amount of protein used was the same as for the MSA incubation experiment. After incubation, the samples were analysed as described above.
Pharmacokinetics. Five nanomoles of NHS-fluorescein-labelled (Thermo Fisher Scientific) αPD-1-ABD-PE or αPD-1-PE was injected intraperitoneally into C57BL/6 mice. At each pre-determined time point (0. 25, 1, 2, 4, 8, 12, 24 , or 48 h after dosing), a cohort of three mice was killed, and blood was collected for quantification of protein concentration. Plasma concentrations of the proteins were determined according to the fluorescence intensity (excitation 494 nm, emission 518 nm). The pharmacokinetics of the proteins were analysed using noncompartmental analysis (Phoenix WinNolin software v.8.0, Pharsight) 58 . The pharmacokinetic parameters CL, t 1/2 , AUC 0-t , and V d were calculated.
Disease delay study with a spontaneous T1D model. Twelve-week-old female NOD mice were randomly assigned into three groups. The three groups were treated intraperitoneally, weekly, with αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), or PBS until the mice were found to be diabetic. Blood glucose levels of these mice were monitored twice weekly using a OneTouch UltraMini Blood Glucose Meter (LifeScan). Onset of T1D was confirmed for a mouse when its blood glucose concentration was greater than 2.5 mg ml −1 for two consecutive measurements. Diabetes-free survival was analysed by the Kaplan-Meier method followed by the log-rank (Mantel-Cox) test using GraphPad Prism v.5.
Disease delay study with a cyclophosphamide-accelerated T1D model. Tenweek-old female NOD mice were injected intraperitoneally with cyclophosphamide (Santa Cruz Biotechnology) at 200 mg per kg (body weight). Two days later, these mice were randomly assigned into three groups. The three groups were treated intraperitoneally with αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), or PBS every other day for a total of five treatments. The diabetes-free survival data were generated and analysed as described above.
Disease delay study with a αPD-1-accelerated T1D model. Ten-week-old female NOD mice were randomly assigned into three groups. The three groups were treated intraperitoneally with αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), or PBS every other day for a total of five treatments. Two days after the last dose, 0.5 mg anti-PD-1 IgG (clone RMP1-14) 27 was administered intraperitoneally to each mouse. Two days later, the mice were given four additional doses of αPD-1 IgG at two-day intervals with a dose of 0.25 mg per mouse per injection. The diabetes-free survival data were collected and analysed as described above.
Examination of immune cells in pancreases, blood and peripheral lymphatic organs of pre-diabetic NOD mice.
Eighteen-week-old, prediabetic, female NOD mice were randomly assigned into three groups. The three groups were treated intraperitoneally with one dose of αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 scFv (2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)) or PBS. Three days later, these mice were euthanized and perfused with 30 ml PBS. Pancreases were collected and a single cell preparation was generated from each of the pancreases by mincing the pancreas tissue with scissors and digesting them with 1 mg ml −1 collagenase IV at 37 °C for 30 min as described previously 59 . The pancreatic cell preparations were filtered through a nylon mesh and dead cells were first stained with 3 µM DAPI for 10 min and then washed three times by centrifugation (300g for 5 min) to remove DAPI. Cells were then stained with PE-conjugated B220 antibody, PE-conjugatated CD8 antibody, PE-Cy7-conjugated CD3 antibody, FITC-conjugated CD4 antibody, PEconjugated FOXP3 antibody (all antibodies were purchased from Biolegend), and Alexa Fluor 647-conjugated PD-1 antibody (made in house). Lastly, 400,000 live cells per pancreatic cell preparation were analysed by flow cytometry with a BD FACSCanto Analyzer.
To analyse immune cells in blood and peripheral lymphatic organs of these mice, blood, spleens and lymph nodes (accessory axillary lymph nodes and subiliac lymph nodes) were collected. Red blood cells were lysed with ammoniumchloride-potassium (ACK) lysing buffer. The remaining cells were pelleted by centrifugation at 300g for 5 min, and stained with DAPI (3 µM), PE-conjugated B220 antibody, PE-conjugated CD8 antibody, PE-Cy7-conjugated CD4 antibody, FITC-conjugated CD3 antibody, PE-conjugated FOXP3 antibody, and Alexa Fluor 647-conjugated PD-1 antibody. Lastly, 10,000 live cells per cell preparation were analysed by flow cytometry with a BD FACSCanto Analyzer.
Disease reversal study in an EAE model. Ten-week-old female C57BL/6 mice were subcutaneously immunized with 0.2 mg MOG peptide (MEVGWYRSPFSRVVHLYRNGK, Biomatik) per mouse. The peptide was emulsified in 0.2 ml complete Freund's adjuvant (CFA, Sigma). Four hours later, the mice were injected intraperitoneally with 200 ng pertussis toxin (List Biological Labs), and an additional 200 ng pertussis toxin 24 h later. The immunized mice were examined for paralysis symptoms every other day from the ninth day after immunization. The symptoms were scored on the basis of a common standard 60 : 1.0, limp tail or isolated weakness of gait without limp tail; 2.0, partial hind-leg paralysis; 3.0, total hind-leg or partial hind-and front-leg paralysis; 4.0, total hind-leg and partial front-leg paralysis; 5.0, moribund or dead animal. At the same time, the immunized mice were randomly assigned into three groups; each group would receive one of the three treatments: αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), or PBS. When an immunized mouse developed severe EAE (clinical score 3.0), this mouse would be immediately treated according to its group assignment. All the treated mice were monitored continuously until they reached their humane endpoint or the end of the study.
Examination of immune cells in pancreases, blood and peripheral lymphatic organs of mice with EAE.
Ten-week-old female C57BL/6 mice were induced for EAE as described above. After all induced mice developed severe EAE (clinical score 3.0), the mice were randomly assigned into three groups that received αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg/kg), or PBS intraperitoneally. Three days later, these mice were euthanized and perfused with 30 ml PBS after blood was collected. The spinal cord and brain were collected, and were subsequently minced and digested as described above. A single cell preparation was made by filtering the processed tissues of one mouse through a nylon mesh. Mononuclear cells were enriched in the preparations by passing the preparations through a discontinuous 30%:70% Percoll gradient as described previously 61, 62 . The resultant cell preparations were stained and analysed by flow cytometry. Dead cells were first stained with 3 µM DAPI for 10 min, and then washed 3 times by centrifugation (300g for 5 min) to remove DAPI. Then cells were stained with PE-conjugated B220 antibody, PE-conjugated CD8 antibody, PE-Cy7-conjugated CD3 antibody, FITC-conjugated CD4 antibody, PE-conjugated FOXP3 antibody (antibodies were purchased from Biolegend), I-Ab MOG [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] -PE tetramer (provided by NIH tetramer care facility), and Alexa Fluor 647-conjugated PD-1 antibody. Lastly, 200,000 live cells per cell preparation were analysed by flow cytometry with a BD FACSCanto Analyzer.
To analyse immune cells in blood and peripheral lymphatic organs of these mice, the blood, spleens and lymph nodes (accessory axillary lymph nodes and subiliac lymph nodes) were collected. Red blood cells were lysed withACK lysing buffer. The remaining cells in the samples were pelleted by a centrifugation at 300g for 5 min, and then cells were stained with DAPI (3 µM), PE-conjugated B220 antibody, PE-conjugated CD8 antibody, PE-Cy7-conjugated CD4 antibody, FITC-conjugated CD3 antibody, PE-conjugated FOXP3 antibody, and Alexa Fluor 647-conjugated PD-1 antibody. Lastly, 10,000 live cells per cell preparation were analysed by flow cytometry with a BD FACSCanto Analyzer.
Fraction analysis of peripheral lymphocytes in healthy NOD and C57BL/6 mice.
Ten-week-old female NOD mice were randomly assigned into four groups and treated with one dose of αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), PBS, or cyclophosphamide (200 mg per kg (body weight)) (Santa Cruz Biotechnology) intraperitoneally. These mice were euthanized 24 h later. Blood samples and splenocytes were collected, and red blood cells were lysed with ACK lysing buffer. The remaining cells in the samples were pelleted by centrifugation at 300g for 5 min, and stained with APC-conjugated B220 antibody (Biolegend), PE-conjugated CD4 antibody (Biolegend), or PE-conjugated CD8α antibody (Santa Cruz Biotechnology). The B220 + , CD4 + and CD8 + fractions in the pellets were analysed by flow cytometry on a BD FACSCanto Analyzer. The same experiment was conducted on 10-week-old female C57BL6 mice.
Evaluation of humoral responses. Ten-week-old female NOD mice were randomly assigned into four groups and treated once or five times with αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), PBS, or cyclophosphamide (200 mg per kg (body weight)) (Santa Cruz Biotechnology) intraperitoneally. Two days after the last treatment, mice were immunized with 100 µg DNP-Ficoll (Biosearchtech) intraperitoneally. Five days after the immunization, serum samples were collected from these mice to determine anti-DNP IgM levels using an enzyme-linked immunosorbent assay (ELISA) as previously described, with some modification 46 . Specifically, serum dilutions from 10 2 to 10 6 folds were applied to ELISA plates pre-coated with DNP-BSA (Thermo Fisher Scientific Inc) (1 μg per well, 4 °C, overnight). After unbound IgM was washed away, a secondary antibody, anti-mouse IgM (µ chain)-horseradish peroxidase conjugate (Jackson ImmunoResearch) (1:5,000 diluted in PBS with 1% BSA) was added to the plates. After a 1h incubation at room temperature, the unbound secondary antibody was washed away, and a TMB substrate (Biolegend) was added to the plates. The plates were then incubated in the dark at room temperature for 20 min for the colourimetric reaction to develop. The reaction was stopped with 2 M H 2 SO 4 . Both A 450 and A 570 (background) were measured. The same diluted serum samples were also applied to ELISA plates pre-coated with the BSA control (Sigma) (1 μg per well, 4 °C, overnight) to determine the non-specific binding of IgM to the plates. All other procedures were the same as for the DNP-Ficoll sample.
The same experiment was also performed with 10-week-old female C57BL/6 mice.
Evaluation of CTL responses. Ten-week-old female NOD mice were randomly assigned to four groups and treated with a single dose of αPD-1-ABD-PE (5 mg per kg (body weight)), a mixture of αPD-1 (scFv, 2.5 mg per kg (body weight)) and ABD-PE (2.5 mg per kg (body weight)), PBS, or cyclphosphamide (200 mg per kg (body weight)) (Santa Cruz Biotechnology) intraperitoneally. Two days later, they were subcutaneously immunized with 10 nmol TYQRTRALV (influenza A nucleoprotein residues 147-155, Biomatik). The peptide was emulsified in incomplete Freund's adjuvant (Sigma). Seven days after the first immunization, the mice were immunzed a second time. Ten days after the second immunization, the mice were killed, and an enzyme-linked immune absorbent spot (ELISpot) assay was performed with splenocytes collected from them as previously described 52, 53 . In a similar manner, ten-week-old female C57BL/6 mice were treated and immunized with 10 nmol of SIINFEKL (ovalbumin residues 257-264). SIINFEKLspecific CTL responses were evaluated as described above.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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